ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2242

Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2395

Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
Abstract Number: 1044

Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Abstract Number: 1934

Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-Methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
Abstract Number: 1274

Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Abstract Number: 2397

Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Abstract Number: 0711

Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
Abstract Number: 2398

Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Abstract Number: 2120

Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
Abstract Number: 0729

ANCA-associated vasculitis – does the type matter?
Abstract Number: 0086

Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Abstract Number: 1436

Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Abstract Number: 0286

Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients
Abstract Number: 1547

Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
Abstract Number: 1548

Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].